<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00344422</url>
  </required_header>
  <id_info>
    <org_study_id>CR002434</org_study_id>
    <nct_id>NCT00344422</nct_id>
  </id_info>
  <brief_title>Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma</brief_title>
  <official_title>A Multi-Center Randomized Study of Vincristine, Doxil and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how well newly diagnosed multiple myeloma patients&#xD;
      respond to an experimental regimen of Vincristine, DOXIL (doxorubicin HCl liposome injection)&#xD;
      and Dexamethasone (VDD) versus the standard treatment of Vincristine, Doxorubicin and&#xD;
      Dexamethasone (VAD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open label study comparing the efficacy, clinical benefit, toxicity and&#xD;
      safety of the combination of Vincristine, DOXIL® (doxorubicin HCl liposome injection), and&#xD;
      Dexamethasone (VDD) to the standard regimen of Vincristine, Doxorubicin and Dexamethasone&#xD;
      (VAD) in patients with newly diagnosed multiple myeloma. Approximately 200 patients with&#xD;
      newly diagnosed multiple myeloma will be randomized to receive either VDD or VAD. This study&#xD;
      will determine and compare the objective response rate (the percentage of patients who attain&#xD;
      an Objective Status of Complete Remission, Remission or Partial Remission) for patients&#xD;
      receiving VDD vs. VAD. This study will also evaluate and compare the clinical benefit of VDD&#xD;
      vs. VAD for the following measures: Hospitalization; Documented sepsis; Antibiotic use; Grade&#xD;
      3 or 4 neutropenia or neutropenic fever.&#xD;
&#xD;
      VDD: Vincristine 1.4 mg/m2 IV on Day 1; Doxil® 40 mg/m2 IV on Day 1; Dexamethasone 40 mg/day&#xD;
      oral Days 1-4; VAD: Vincristine 0.4 mg/day continuous infusion Days 1-4; Doxorubicin 9.0&#xD;
      mg/m2/day continuous infusion Days 1-4; Dexamethasone 40 mg/day orally on Days 1-4; Every 28&#xD;
      days for 4 cycles&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine and compare the objective response rate (the percentage of patients who attain an Objective Status of Complete Remission, Remission or Partial Remission) for patients receiving VDD vs VAD.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate and compare the clinical benefit of VDD vs VAD for the following measures: Hospitalization, Documented sepsis,Antibiotic use, Grade 3 or 4 neutropenia or neutropenic fever</measure>
  </secondary_outcome>
  <enrollment type="Actual">198</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Myeloma</condition>
  <condition>M-Protein</condition>
  <condition>Myeloma Proteins</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Untreated multiple myeloma requiring treatment&#xD;
&#xD;
          -  Total cumulative dose of prior doxorubicin can not exceed 240 mg/m2&#xD;
&#xD;
          -  Must have measurable disease&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction (LVEF) &gt;= 50 % determined by Multiple Gated&#xD;
             Acquisition Scan (MUGA)&#xD;
&#xD;
          -  Karnofsky performance status of &gt;= 60%&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function&#xD;
&#xD;
          -  Disease-free from prior malignancies &gt;= 5 years with the exception of basal cell or&#xD;
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Female participants (if of child bearing potential and sexually active) and male&#xD;
             participants (if sexually active with a partner of child-bearing potential) must use&#xD;
             medically acceptable methods of birth control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy of &gt;= 3 months&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  History of cardiac disease, with New York Heart Association Class II or greater, with&#xD;
             congestive heart failure&#xD;
&#xD;
          -  or unstable angina, uncontrolled hypertension or cardiac arrythmias or myocardial&#xD;
             infarction within the last 6 months&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus or systemic infection&#xD;
&#xD;
          -  Nonsecretory myeloma, Monoclonal Gammopathy of Unknown Significance (MGUS) or&#xD;
             smoldering myeloma&#xD;
&#xD;
          -  Confusion, disorientation, or history of psychiatric illness which may impair&#xD;
             patient's ability to give informed consent&#xD;
&#xD;
          -  Prior chemotherapy to treat Multiple Myeloma&#xD;
&#xD;
          -  Prior radiotherapy to an area greater than 1/3 of the skeleton&#xD;
&#xD;
          -  Prior local radiotherapy within 1 week of treatment&#xD;
&#xD;
          -  Any investigational agent within 30 days of the first dose of treatment&#xD;
&#xD;
          -  Prior single agent dexamethasone (or another corticosteroid) to treat Multiple&#xD;
             Myeloma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=479&amp;filename=CR002434_CSR.pdf</url>
    <description>A Multi-Center Randomized Study of Vincristine, DOXIL and Dexamethasone vs. Vincristine Doxorubicin, and Dexamethasone in Patients with Multiple Myeloma</description>
  </link>
  <results_reference>
    <citation>Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer. 2006 Feb 15;106(4):848-58.</citation>
    <PMID>16404741</PMID>
  </results_reference>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>June 23, 2006</study_first_submitted>
  <study_first_submitted_qc>June 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2006</study_first_posted>
  <last_update_submitted>June 8, 2011</last_update_submitted>
  <last_update_submitted_qc>June 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <keyword>Anthracyclines</keyword>
  <keyword>Liposomes</keyword>
  <keyword>Liposomal</keyword>
  <keyword>Vincristine</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Pegylated Liposomal Doxorubicin</keyword>
  <keyword>DOXIL</keyword>
  <keyword>drug resistant myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

